Azacitidine Plus APR-246 Appears Promising as Treatment of TP53-Mutant MDS and AML
Thomas Cluzeau, MD, PhD, discusses the rationale for evaluating azacitidine in combination with APR-246 in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.
